Show results for
Refine by
Applications
- Solutions for Endometriosis
- Solutions for Severe but Non-Specific Symptoms
- Microbiome Therapeutics for Clinical Trials
- Pipeline for Infectious Diseases
- Pipeline for Immuno-Oncology
- Pipeline for Precision Medicine
- Affilin - Precision Targeting Technology for Protein Drug Conjugates
- Affilin - Precision Targeting Technology for Radio Conjugates
- Affilin - Precision Targeting Technology for Cellular Therapies
- Affilin - Precision Targeting Technology for Multispecific Ligands
Drug Platform Candidate Equipment & Supplies
115 equipment items found
by:Enveric Biosciences, Inc. based inNaples, FLORIDA (USA)
Every molecule in the Psybrary™ is screened through PsyAITM, a proprietary artificial intelligence (AI) tool. Leveraging AI systems reduces the time and cost of commercial development. It streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities and pharmacological effects to help determine ideal drug candidates, tailored to each ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX and Amgen are developing CX-904, a T-cell engaging bispecific Probody candidate against Epidermal Growth Factor Receptor (EGFR) and CD3. The drug candidate is advancing towards IND-enabling studies. CytomX is responsible for the IND filing, targeted for late 2021, and for early clinical development with Amgen leading later stage development and ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the agreement, we are responsible for executing a research program funded by Indivior to discover novel drug candidates. Indivior has the right to select GABAB PAM drug candidates from our research ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
We are developing metabotropic glutamate receptor subtype 7, or mGlu7 NAM as a novel orally available treatment to reduce fear memory in PTSD. This is a disorder that can lead to intense fear and anxiety. Current medication is unspecific and ineffective, with a number of side effects. By selectively targeting mGlu7 with NAMs, the brain circuitries involved in fear and anxiety can be more ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelocImmune is our unique technology for producing fully human monoclonal antibodies. VelocImmune creates a multitude of optimized antibody drug candidates efficiently and directly from immunized mice. This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic ...
Manufactured by:Krieger AG based inMuttenz, SWITZERLAND
With a starting minimum volume of 25 ml, the Micro Mixer range is the ideal tool to scale down your contained mixing processes under pressure or vacuum. Dissolution of expensive shear sensitive API's, proteins, Developing and processing small molecule and complex biologic drug candidates. Or just vacuum ...
Manufactured by:GENFIT based inLoos, FRANCE
We are conducting a research program to develop an anti-fibrotic drug candidate, with a priority given to liver fibrosis. This program consists in a repositioning of Nitazoxanide, or NTZ*, that is being investigated for the treatment of fibrosis in pre-clinical disease models. NTZ is currently being evaluated in an investigator-initiated proof-of-concept clinical trial for the potential ...
by:Ainovo Biotech Inc. based inSacramento, CALIFORNIA (USA)
AlOptimus™ brings to bear AINovo's proprietary machine learning algorithms on our highly curated datasets to enhance the therapeutic profiles of drug candidates. The AlOptimus platform optimizes validated candidates to derisk development and inform clinical ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
MolEQ designs novel compounds by optimizing multiple properties such as efficacy and toxicity of a lead ...
Manufactured by:Inoviem Scientific SAS based inIllkirch-Graffenstaden, FRANCE
Identify a cohort of patients responding to your therapy with PIMS® technology; PIMS is a label-free technology based on the dynamic molecular resonance of proteins and ...
Manufactured by:iMouse GmbH based inBerlin, GERMANY
The DigiFrame's cameras, equipped with autofocus and wide-angle lenses, are tailored to offer optimal cage views and adaptability. Its intelligent Vision AI and machine learning platform aids scientists in refining the prediction of new drug candidates, enhancing translation from preclinical to clinical phases while minimizing failure ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
The drug candidate GS-659, which is sprung from Gesynta Pharma’s drug development platform, is currently in preclinical development phase. Project updates will be announced in due ...
Manufactured by:Eupraxia Pharmaceuticals based inVictoria, BRITISH COLUMBIA (CANADA)
Our patented technology is designed to be tailored to a wide variety of drugs and therapeutic indications. In addition to our lead drug candidate (EP-104IAR), Eupraxia is currently developing an extended-release post-surgical anesthetic (EP-105) and antibiotic (EP-201). Eupraxia hopes to add 1-2 additional candidates to our pipeline within the next year, including an internally developed oncology ...
Manufactured by:BioFactura, Inc. based inFrederick, MARYLAND (USA)
BioFactura develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFastTM Biomanufacturing Platform, the optimal choice for bringing these drug to market with faster, lower cost, superior-quality manufacture. The global biosimilars market is projected to grow from $4.5B in 2017 to over $23B by 2023 with a Compound ...
by:STALICLA based inGeneve, SWITZERLAND
DDU validates ASD phenotype groups and drug candidates through observational studies and investigational trials. DDU combines expertise in operations, medicine, drug and clinical development, to bring STALICLA’s clinical-stage treatment options closer to ...
Manufactured by:Confo Therapeutics based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying ...
Manufactured by:Navigo Proteins GmbH based inHalle, GERMANY
Navigo Proteins’ Precision Targeting unit leverages its protein engineering expertise to create proprietary Affilin® molecules, harnessed to create optimized, next generation biopharmaceutical drugs in numerous fields of use. Navigo Proteins’ Affilin® platform benefits from the inherent engineerability, stability, safety, and ease of ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
The drug candidate ABBV-0805 is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. The goal is to develop a disease modifying treatment that stops or slows down disease ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our license agreement with Indivior provides for a funded research program, under which we have the right to select drug candidates for exclusive development in certain indications outside of SUD. We plan to develop our selected drug candidates in CMT1a, chronic cough and pain. These indications have been validated with baclofen, an orthosteric agonist of GABAB and present a significant unmet ...